Rituximab-induced Crohn’s disease

Varma, Poornima; Falconer, Julianne; Aga, Ahmad; Prince, H. Miles; Pianko, Stephen

doi:10.1080/00365521.2017.1280530

Cited by 36 publications

(25 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IBD: “There are reports of rituximab-associated ulcerative colitis; however, we report for the first time, two cases of rituximab-induced Crohn's disease in elderly patients treated for lymphoma.” [ 126 ]…”

Section: Commonality Of Contributing Factors Between Ibd and Id - Detailsmentioning

confidence: 99%

Common contributing factors to COVID-19 and inflammatory bowel disease

Kostoff

Briggs²,

Kanduc

et al. 2021

Toxicology Reports

View full text Add to dashboard Cite

show abstract

Section: Commonality Of Contributing Factors Between Ibd and Id - Detailsmentioning

confidence: 99%

Common contributing factors to COVID-19 and inflammatory bowel disease

Kostoff

Briggs²,

Kanduc

et al. 2021

Toxicology Reports

View full text Add to dashboard Cite

show abstract

“…A total of 35 cases of UC, Crohn's disease, MC, and ileocolitis induced by RTX have been reported. Thirteen patients had RTX-induced UC (6,8,11,14), 11 had RTX-induced Crohn's disease (7,8,15,16), 9 had RTX-induced MC, and patients had ileocolitis (9), including our case.…”

Section: Discussionmentioning

confidence: 63%

Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review

et al. 2021

View full text Add to dashboard Cite

Rituximab (RTX) is effective for treating cancer, but reports of RTX-associated enterocolitis are limited. We herein report the case of a 65-year-old man who developed RTX-induced ileocolitis. He was diagnosed with gastric mucosa-associated lymphoid tissue lymphoma (MALToma) and treated with RTX. He complained of bloody diarrhea after RTX. Mucosal inflammation on colonoscopy indicated RTX-induced ileocolitis. He was treated with corticosteroids, and his symptoms improved. We reviewed the RTX-associated gastrointestinal adverse events and classified the features into ulcerative colitis, Crohn's disease, microscopic colitis, and ileocolitis. To our knowledge, this is the first case of a Japanese patient who developed RTXinduced ileocolitis.

show abstract

“…Rituximab is an anti-CD20 monoclonal antibody that has been used in the management of a form of B-cell targeted therapy in rheumatoid arthritis and low-grade lymphoma [ 62 - 64 ]. Rituximab therapy results in a depletion of systemic as well as intestinal B cell populations.…”

Section: Anti-tumoral Agentsmentioning

confidence: 99%

“…Recently, one report described two cases of CD in two patients with small lymphocytic lymphoma and grade 2 follicular non-Hodgkin’s lymphoma with an interval of 3 months and 22 months after completion of the treatment. One case involved the colon and the other affected the ileum with biopsies demonstrating neutrophilic inflammation, ulcer, and non-caseating granulomata [ 62 ] ( Fig. 5 ).…”

Section: Anti-tumoral Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature

et al. 2018

View full text Add to dashboard Cite

An increasing number of drugs including monoclonal antibodies and small molecules, either anti-inflammatory or immunity-enhancing, have been developed to treat human diseases and the number of medications in these classes is likely to expand in the future. The two most commonly used categories of such therapies are the anti-inflammatory group (anti- tumor necrosis factor (TNF) α, anti-interleukins/interleukin receptors, and anti-integrin bodies) and the anti-tumoral agents (immune checkpoint inhibitors, anti-CD20, and anti-endothelial growth factor). Although the anti-inflammatory biologics have brought about a revolutionary effect in the management of a variety of autoimmune disorders including rheumatologic diseases, inflammatory bowel disease, and inflammatory dermatological diseases, their ability to induce colitis in patients without a prior history of colitis or exacerbate quiescent colitis has been increasingly and unexpectedly recognized. While the use of immune-augmenting monoclonal antibody therapies results in a significant survival benefit in a subset of patients with malignancies, these monoclonal antibodies also have the ability to cause colitis through an apparent autoimmune mechanism. Colitis associated with these medications may demonstrate multiple histologic patterns including increased apoptosis (graft versus host disease (GVHD)-like), autoimmune enteropathy pattern, acute colitis pattern, ischemic colitis, inflammatory bowel disease pattern, either ulcerative colitis-like, Crohn’s disease-like, or fulminant colitis-like. In addition, anti-inflammatory biologics are known to cause or reactivate latent infections such as tuberculosis and increase the risk for malignancies including high-grade lymphomas as well as indolent lymphoproliferative disorders. Thus, the differential diagnosis for colitis in patients receiving therapeutic anti-inflammatory biologics or anti-tumoral agents can be broad. Optimal diagnosis and treatment requires a multidisciplinary approach. This review aims to provide an overview of the literature on the clinical features, histology, and treatment of these newly recognized anti-inflammatory biologic and anti-tumoral immune therapy-induced colitises and hopes this outlines will raise the vigilance of all clinicians of these entities.

show abstract

Rituximab-induced Crohn’s disease

Cited by 36 publications

References 13 publications

Common contributing factors to COVID-19 and inflammatory bowel disease

Common contributing factors to COVID-19 and inflammatory bowel disease

Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review

Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature

Contact Info

Product

Resources

About